The Latest Breaking News from Pfizer

Morning Markets December E-Mini S&P 500 futures (ESZ2 3) are up +0.17%, and Dec Nasdaq 100 E-Mini futures (NQZ2 3) are up +0.31%. Stock index futures this morning are moderately higher after the U.S. Nov CPI report matched expectations and eased slightly, bolstering speculation the Fed will start cutting interest...

Two new COVID-19 vaccines targeting the new Omicron variant of the virus are now available in Australian pharmacies around the nation.

Pfizer shares sank Friday when the drugmaker announced that it was abandoning a twice-daily obesity treatment after more than half the patients in a clinical trial stopped taking it

Pfizer said Friday it would not advance development of a twice-daily oral weight-loss drug because of its side effects.

State attorney general Ken Paxton files suit despite medical consensus that vaccine prevents severe infection and death

The Innovator IBD 50 ETF outperformed with a 0.6% gain and could make its first close above the 200-day moving average since Sept. 12.

Pfizer will retool its obesity drug efforts, but the delay is a blow to the group's ambitions to challenge Novo Nordisk and Lilly in the fast-developing space.

Experts argue other assertions made in the lawsuit filing are completely unsubstantiated, such as one claiming that vaccinated people were more likely to die from COVID-19, which Texas health data disputes.

Unlike many of its peers, GSK just reported a big year-over-year jump in vaccine sales - and there's more growth to come, as the pharmaceutical company expands both its pipeline and the geographical reach for its vaccines.